Pamela Lawrence Endreny

Pamela Lawrence Endreny is a partner in the New York office of Gibson Dunn and a Co-Chair of the firm’s Tax Practice Group.

Pamela represents clients in a broad range of U.S. tax matters. Her experience includes mergers and acquisitions, spin-offs, investment funds, joint ventures, financings, and capital markets transactions.  

She has been repeatedly selected for inclusion in Chambers USA: America’s Leading Lawyers for Business and The Legal 500 US and was also named a Tax “MVP” by Law360.

Pamela is a member of the Executive Committee of the New York State Bar Association Tax Section. She is also a member of the Tax Forum and Private Investment Funds Tax Forum.

Significant representations include:

• Exxon Mobil Corporation on its redomestication to Texas;
• Modine, on a Reverse Morris Trust, including the spin-off and combination of Modine’s Performance Technologies business with Gentherm;
• AT&T on its $5.75 billion acquisition of Lumen’s mass markets fiber business;
• Berkshire Residential Investments on its $1.99 billion Bridge Loan Investors III, $1.4 billion Credit Fund IV, and $1.5 billion Value Fund V;
• Appian Capital Advisory on its $2 billion Appian Natural Resources Fund III, a global metals and mining fund;
• Otro Capital on its $1.2 billion inaugural sports buyout fund, Otro Capital Fund I;
• Hahn & Company on its $3.4 billion Korea-focused buyout fund, Hahn & Company IV;
• Affiliated Managers Group on its investment in NorthBridge Partners, a real estate investment management firm;
• RidgeLake Partners on numerous General Partner stakes investments;
• Lennar Corporation on the spin-off of Millrose Properties, Inc.;
• VMware in its $61 billion acquisition by Broadcom;
• Ziff Davis in its spin-off of Consensus Cloud Solutions, Inc.;
• Wrexham AFC and its owners, Ryan Reynolds and Rob Mac, on Apollo Sports Capital’s minority investment in Wrexham AFC;
• A group led by Ryan Reynolds and Hugh Jackman on their acquisition of a controlling stake in Australia’s SailGP team, the Bonds Flying Roos;
• Merck on its $9.2 billion acquisition of Cidara Therapeutics, Inc.;
• Gyre Therapeutics, Inc., on its acquisition of Cullgen Inc. in an all-stock merger valued at approximately $300 million;
• 89bio, Inc., on its up to $3.5 billion sale to Roche Holdings, Inc.;
• XOMA Royalty on XenoTherapeutics, Inc. and Xeno Acquisition Corp.’s acquisition of Repare Therapeutics Inc.;
•  Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead.

Capabilities

• Tax
• Investment Funds
• Mergers and Acquisitions
• Private Equity
• Real Estate
• Real Estate Investment Trust (REIT)

Credentials

Education:

• Columbia University - 1994 Juris Doctor
• Brown University - 1986 Bachelor of Arts

Admissions:

• Massachusetts Bar
• New York Bar